Catalyst Wire Dossier Catalyst Wire Dossier
FDA approval · 2022-07-29

FDA Approved: BUPHENYL — Supplemental Application (Horizon Therapeutics USA, Inc.)

View source ↗

Summary

FDA approved a supplemental application for BUPHENYL (sodium phenylbutyrate) from Horizon Therapeutics USA, Inc., resulting in updated labeling for the product.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • BUPHENYL (Sodium phenylbutyrate)

Snippet

SUPPL AP for BUPHENYL (SODIUM PHENYLBUTYRATE)